Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors

Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors (TKIs) are part of the standard treatment strategy in patients with metastatic disease. However, there are still no established biomarkers to predict clinical benefits of a specific TKI. Here, we perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahiri, Andliena, Puco, Katarina, Naji, Faris, Kristensen, Vessela N., Alfsen, Glenny Cecilie, Farkas, Lorant, Nilsen, Frode S., Müller, Stig, Oldenburg, Jan, Geisler, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450987/
https://www.ncbi.nlm.nih.gov/pubmed/36093296
http://dx.doi.org/10.18632/oncotarget.28257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450987/
https://www.ncbi.nlm.nih.gov/pubmed/36093296
http://dx.doi.org/10.18632/oncotarget.28257

Ejemplares similares